CAMBRIDGE, Mass., Sept. 23, 2011 /PRNewswire/ -- Efficacy and safety data from VELOUR, the pivotal Phase III trial of aflibercept (VEGF Trap, ZALTRAP) for the treatment of metastatic colorectal cancer (mCRC) will be presented by Edith P. Mitchell, M.D., a leading cancer researcher, at the Angiogenesis Foundation’s 9th Annual M. Judah Folkman International Conference: Antiangiogenesis: New Frontiers in Therapeutic Development on October 29-30, 2011 at the Hyatt Regency Cambridge.
The VELOUR presentation will be the first time the results are presented in the U.S.
Registration for the conference is now open. To review the topic and speaker agenda visit http://www.angio.org/programs-cp-aa11.php.
Dr. Mitchell will join a roster of distinguished speakers at the conference, including Dr. Robert S. Kerbel of the University of Toronto, and Dr. Adriana Albini of IRCCS Multimedica, Italy.
This year’s conference will include presentations by leaders from Harvard Medical School, the U.S. National Cancer Institute, University of Texas MD Anderson, Memorial Sloan Kettering Cancer Center, Stanford University, Queen’s University Belfast, Johannes Gutenberg University Mainz, IRCCS Multimedica Milan, and other top research institutions.
Topics to be covered at this year’s meeting include:
- Anti-VEGF therapy resistance and antiangiogenic escape
- VEGF-independent tumor angiogenesis
- Glioblastoma vasculature and stem cells
- Novel therapy biomarkers
- Early intervention and prevention through antiangiogenesis
As the world’s leading non-profit organization dedicated to advancing the field of angiogenesis research, the Angiogenesis Foundation takes a multidisciplinary approach to its annual conference, bringing together experts and key stakeholders from basic research, life sciences industry, clinical investigation, and government to foster new collaborations and exchanges between faculty and attendees.
Due to limited space, early registration is encouraged. For additional information please contact, Michelle Sylvanowicz at (617) 401-2779.
SOURCE The Angiogenesis Foundation
